key: cord-0819840-648ut8de
authors: Ferreira, Gonzalo; Santander, Axel; Savio, Florencia; Guirado, Mariana; Sobrevia, Luis; Nicolson, Garth L.
title: SARS-CoV-2, Zika viruses and mycoplasma: structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases
date: 2021-09-03
journal: Biochim Biophys Acta Mol Basis Dis
DOI: 10.1016/j.bbadis.2021.166264
sha: bfc218eea98af9aef8844802d6f52a4cec40be56
doc_id: 819840
cord_uid: 648ut8de

The molecular evolution of life on earth along with changing environmental, conditions has rendered mankind susceptible to endemic and pandemic emerging infectious diseases. The effects of certain systemic viral and bacterial infections on morbidity and mortality are considered as examples of recent emerging infections. Here we will focus on three examples of infections that are important in pregnancy and early childhood: SARS-CoV-2 virus, Zika virus, and Mycoplasma species. The basic structural characteristics of these infectious agents will be examined, along with their general pathogenic mechanisms. Coronavirus infections, such as caused by the SARS-CoV-2 virus, likely evolved from zoonotic bat viruses to infect humans and cause a pandemic that has been the biggest challenge for humanity since the Spanish Flu pandemic of the early 20(th) century. In contrast, Zika Virus infections represent an expanding infectious threat in the context of global climate change. The relationship of these infections to pregnancy, the vertical transmission and neurological sequels make these viruses highly relevant to the topics of this special issue. Finally, mycoplasmal infections have been present before mankind evolved, but they were rarely identified as human pathogens until recently, and they are now recognized as important coinfections that are able to modify the course and prognosis of various infectious diseases and other chronic illnesses. The infectious processes caused by these intracellular microorganisms are examined as well as some general aspects of their pathogeneses, clinical presentations, and diagnoses. We will finally consider examples of treatments that have been used to reduce morbidity and mortality of these infections and discuss briefly the current status of vaccines, in particular, against the SARS-CoV-2 virus. It is important to understand some of the basic features of these emerging infectious diseases and the pathogens involved in order to better appreciate the contributions of this special issue on how infectious diseases can affect human pregnancy, fetuses and neonates.

According to the U.S. National Institute of Allergy and Infectious Diseases, emerging infectious diseases are commonly defined as outbreaks of previously unknown diseases, in contrast to known persistent diseases that are uncontrolled and rapidly increasing in incidence or geographic range [1] . Emerging infectious diseases should not be confused with reemerging infectious diseases, which are diseases that reappear after they have been in significant decline due to several reasons.

Emerging and reemerging infectious diseases remain among the leading causes of death and disability worldwide. All of these infectious pathogens are subject to changes in their genomes, epigenomes, and their interactions with particular hosts, modifying the susceptibility of populations to new diseases [2] . All emerging and reemerging infectious diseases have to be evaluated in the context of human reproduction [3] . Reproduction is an essential step in the conservation of a species. There can be effects before and after conception. After conception there are many physiological changes related to reproduction that take place in higher organisms, such as in a mammalian mother and its offspring during pregnancy, resulting in adaptations of the individuals within the milieu of mother/placenta-fetus/neonate interactions [4] . Some changes are related to the presence of new individuals, such as changes in maternal breathing, circulation and immunity patterns, and other changes are associated with the generation of a new organ, the placenta, dedicated to the support and relationship between offspring and mother. As a result of the physiological changes that occur during pregnancy, there are also different susceptibilities to trans-epithelial transport could be the enzymes responsible for the cleavage of SARS-CoV-2 S proteins [46] . After cleavage, part S1 of the S protein appears to be responsible for determining the host-virus range and cellular tropism, whereas S2 functions to help mediate virus fusion with host cell membranes. The S protein cleavage products S1 and S2 are two distinct functional domains of the S protein, both of which are necessary for a coronavirus to successfully enter a human cell. A sequence of events occurs after coronavirus S protein sequence S1 attaches to a host epithelial cell membrane via the ACE2 receptor, and eventually the virus enters host cells where it replicates.

Thus, the cleavage of the S glycoprotein into S1 and S2 fragments is important in the endocytosis of the coronavirus and entry into the endosomes of the host cell where it eventually fuses with cellular membranes [47] [48] [49] [50] [51] .

The successful endocytosis of SARS-CoV viruses also requires a type II transmembrane serine protease, an enzyme that in humans is encoded by the gene TMPRSS2 (TMPRSS2). This process is known as priming of the S protein in human lung cells, which is an essential step for viral entry into cells [48] . Hence, the SARS-CoV-2 virions have to be activated for membrane fusion by TMPRSS2 and can thus be inhibited by TMPRSS2 inhibitors [48] . Similar to other SARS-CoV viruses, the SARS-CoV-2 virus uses the ACE2 receptor for entry and the serine protease TMPRSS2 for S protein priming to complete viral endocytosis. After virus fusion occurs, the TMPRSS2 located in the surface of host cells will degrade the ACE2 receptors and activate the receptorattached spike-like S proteins [52, 53] . This priming process of the S protein unmasks the fusion peptide S2 and activates a further membrane fusion within the endosomes [54, 55] . Thus, S2 acts as its distribution in situ on the virion surface have been determined with high-resolution cryo-electron microscopy [13, [48] [49] [50] 57, 58] . The structure of the S protein in its closed conformation (prefusion) is shown in Fig. 2C (PDB 6VXX) [50] . Upon binding of the S protein receptor-binding domain (RBD) to the cell ACE2 receptor, the S protein elongates, facilitating the contact between the virion and the host cell. These results in a post-fusion conformational change are shownin Fig. 2C (PDB 6M3W) [59] . The structure of the RBD bound to the ACE2 receptor has also been determined, and this is shown in Fig. 2C , (PDB 6M17, 7KNI) [60, 61] . Because of its importance in viral-cell binding, the S protein has been used as an important target for vaccines and antiviral therapeutics [62] .

The N protein or coronavirus nucleocapsid protein is a structural and multifunctional protein that forms complexes with genomic viral RNA. It interacts with the other viral membrane proteins during virus assembly. The N protein also plays a critical role in enhancing the efficiency of virus transcription and assembly. It helps package the positive strand viral genome RNA into a helical ribonucleocapsid. In addition, it plays a fundamental role during virus assembly through its interactions with coronavirus membrane protein M. The N protein also plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication [63] .

Amino acid sequence comparisons have shown that SARS-CoV N proteins have three distinct and highly conserved domains, including two structural and independently folded structural regions,

The use of static light scattering, size exclusive chromatography, and small-angle X-ray scattering have shown that the purified N proteins are largely present as dimers in solution. The SARS-CoV N protein has a high percentage of disorder at room temperature, whereas it is more structured at 55 °C. Fluorescence polarization has shown that it has non-specific nucleic acidbinding capability, which raised a concern if it was to be chosen as a diagnostic marker [65] .

Because the N protein is bound to RNA, this protein is involved in processes related to the viral genome, the viral replication cycle, and the cellular response of host cells to viral infections [28, 44] .

The N protein is also heavily phosphorylated, and this has been proposed to result in structural changes that enhance the affinity of N protein to viral RNA [66, 67] . Finally the N protein may modulate transforming growth factor-β signaling by binding the host receptor SMAD3, thereby blocking the apoptosis of infected cells [68] . The crystal structure of the N-terminal region of the N protein has been obtained (PDB 6M3M, green, Fig. 2D , left panel) [69] as well as the crystal structure of the N protein P1 dimerization domain (PDB 6WZO, Fig. 2D , right panel).

The RNAs of CoVs are enveloped, single-stranded, positive-sense RNAs with genome sizes ranging between 26.2-31.7 Kb. Coronavirus genomes are among the largest genomes of RNA viruses [70] . The large, capped and polyadenylated genomes of coronaviruses contain seven common genes in the following conserved order: 5'-ORF1a-ORF1b-S-ORF3-E-M-N-3' [71] . The open reading frames (ORF) 1a/b encompasses two-thirds of the coronavirus genomes and collectively produce a genome-length mRNA (mRNA1) that encodes two overlapping viral replicase proteins called polyproteins 1a (pp1a) and 1b (pp1b) [72] . The S, M, N and E genes encoded proteases into mature nonstructural proteins (nsp1 to nsp16), which in turn assemble to form a membrane-associated viral replicase-transcriptase complex (RTC) [72, 74, 75] . The remaining one-third of the coronavirus genome yields subgenomic (sg) mRNAs that encode the four structural proteins discussed above (S, E, M, and N proteins), as well as a number of accessory proteins [76, 77] . A scheme of the SARS-CoV-2 RNA reference sequences with the different regions specified above, according to NIH, is shown in Fig. 3 .

Inside host cells the duplication of the SARS-CoV-2 virus involves non-structural proteins (nsps). Once the virus enters a host cell, it releases its genomic material into the cytoplasm to begin its replication cycle, as summarized in Fig. 4 . The coronavirus RNA is then transferred to the nucleus for duplication, and the viral mRNA ready for translation is bound by the cell's ribosomes and translated into viral proteins. The genomic material released by coronaviruses contain 14 ORF, each of which encodes a variety of structural and nsps proteins that play roles in cell binding and entry, replication, survival and virulence. The gene segments that encode the nonstructural SARS-CoV-2 polyproteins are translated first into ORF1a and ORF1b to produce two large overlapping polyproteins, pp1a and pp1ab [70] .

The SARS-CoV-2 polyproteins require processing by viral proteases, namely a papain-like protease (PLpro) and a serine-type chymotrypsin-like protease (3CLpro) that are encoded by nsp3 and nsp5, respectively. Subsequently, pp1a and pp1ab are cleaved into nsps proteins 1-11 and 1- typical SARS-CoV-2 virus inside humans accumulates only two single-letter mutations per month in its genome-a rate of change about one-half that of influenza and one-quarter that of HIV-1 [87] .

SARS-CoV-2 has an RNA proofreading mechanism that keeps the mutation rate low in comparison with other viruses. Since its appearance at the end of 2019, many unique strains of SARS-Cov-2 have been detected in different countries [88, 89] . There are also some hot-spot locations that show increased rates of mutations [86, 90] . Sometimes these changes have resulted in an increase in the adaptation of the virus to the host that could facilitate the infectivity of the different viral strains.

This turns out to be very important in locating different virion targets for vaccines and antivirals [90] .

with fever, cough and other symptoms, to life-threatening diseases characterized by severe symptoms of pneumonia with ARDS, multi-organ failure and a high mortality rate. Early prodromal symptoms can include hyposmia, anosmia and dysguesia as well as fever, sore throat, cough, chest tightness, shortness of breath, headaches, myalgias, gastrointestinal (nausea, vomiting, pain and diarrhea) and other symptoms. Highly progressed patients that have severe, lifethreatening disease usually suffer ARDS, excessive inflammation, coagulation and cytokine problems, metabolic acidosis, sepsis and septic shock, and/or multi-organ failure [11, 12, 110] .

The overall mortality rate of COVID-19 is around 3% [111] . The rate of ICU admission is about 5%, and the rate of hospital admission is about 20% [112] . These values can vary among different populations, geographical regions and the types of healthcare systems. The severity of the disease is related to the age of patients and the presence or absence of comorbidities. It is more severe in men than in women. Blood type has also been found to be relevant. Blood type A seems to have the worst prognosis, and O the best prognosis, between the A, B, O types [113, 114] . The lethality of COVID-19 increases dramatically with the age of affected individuals.

COVID-19 symptoms usually appear 2 to 3 days after exposure to an infected individual. The most common mode of transmission is through air droplets, and this implies the utility of some common measures that the WHO has recommended for preventing the spread of this disease, such as physical distance among people, use of protective masks, especially in closed spaces, washing hands thoroughly, and disinfection of places occupied by COVID-19-positive patients [115] . The disease course usually lasts about 14 days, and patients can infect other uninfected individuals, even in pre-symptomatic stages. The more severe the presentation of the disease, the longer it can take to tract are anosmia and dysguesia, or a loss of sense of smell and taste. The loss of smell seems to involve non-neuronal components for the sense of olfaction [117] . Neurons do not have ACE2

receptors, but this receptor is expressed on cells that are essential for support of the olfactory neurons, and also stem cells from blood vessels [117] . These early symptoms have been reported in as much as 90% of SARS-CoV-2-infected, COVID-19-positive patients [110, 118] . These symptoms seem to be more common in mild or nearly asymptomatic cases [119] .

Markov models have been applied to thousands of patients to predict the order of appearance of the following symptoms: fever, cough, sore throat, headache, myalgia with nausea and vomiting [120] . Other sets of common nonspecific symptoms that may appear in any order and can be superimposed on other symptoms, such as fatigue, breathlessness, joint and chest pain, vision problems, lack of appetite, among others [121] . It is interesting that several of the later symptoms can persist for longer periods after the acute phase of the infection and last several weeks or even months after onset of the illness [121] .

Testing and tracing are an invaluable tool in the SARS-CoV-2 pandemic, although several considerations have to be taken into account when interpreting test results [122] [123] [124] Up to December 2020 the virological assays for detecting SARS-CoV-2 routinely used oral or   nasal samples to detect either the SARS-CoV-2 nucleic acids through a nucleic acid amplification technique, such as the Polymerase Chain Reaction (PCR), or the viral antigens using specific immunological reagents. Infected individuals may test positive for viral nucleic acids or proteins without expressing symptoms (asymptomatic), before symptom onset (pre-symptomatic), and after symptoms have occurred (symptomatic) and patients are experiencing the disease [125] [126] [127] [128] [129] [130] [131] . As for any virus, SARS-CoV-2 will continue to acquire genetic changes/mutations over time, and this requires constant updating of testing materials and procedures which can reduce the risk of falsenegative results [132] [133] [134] [135] . The sensitivity of different antigen tests performed using immunological reagents compared to more sensitive nucleic acid detection using RT-PCR in specimens from nasopharyngeal swabs appears to be highly variable [136] [137] [138] . More false positives can occur with the viral antigen detection assays, because the antibodies used sometimes recognize other viral antigens from different CoVs than from the SARS-CoV-2.

Antibody tests can also have different uses. For example, after infection with SARS-CoV-2

there is usually an increase in specific antibodies against the virus that can last for several months and is thought to be an important potential source of anti-viral immunity. Vaccines take advantage of this response, and they elevate the number of specific antibodies against the virus [139] [140] [141] 

Since the appearance of COVID-19, there have been several procedures that have been employed to treat the virus directly as well as some to treat the symptoms and complications that accompany the virus. In addition, there have been efforts to reduce the severity of symptoms and provide adequate patient support. This is especially important in patients that progress to express very severe symptoms requiring ICU support [145, 146] . Finally, procedures have been developed to treat possible co-infections that together with SARS-CoV-2 make the condition more severe and life-threatening [143] . Most of the patients that progress to a severe form of the disease require ICU support, and these are usually older patients that also have underlying health conditions, such as hypertension, diabetes, obesity, cardiovascular and respiratory disease (asthma, emphysema), hemorrhagic or ischemic strokes, immunosuppression, cancer, chronic kidney or liver disease and secondary infections [110, 146, 147] .

In the treatment of SARS-CoV-2 virus infections a variety of anti-inflammatory and antimicrobial agents have been investigated to determine if they have therapeutic potential. Among the first examined were hydroxychloroquine (HCQ) and chloroquine (CQ) (often in combination with azithromycin), and this was followed by the antivirals Remdesivir, Lopinavir, and other antiproliferative agents. HCQ and CQ are more well-known as anti-malarial agents, but they have been used against viral infections, and previously they were found to inhibit the proliferation of SARS viruses in cell cultures [148, 149] .

Pilot studies revealed that CQ and HCQ could, in fact, inhibit viral infections in patients [150, 151] . The action of CQ and HCQ during SARS infections may revolve around their abilities to increase endosome internal pH and prevent Toll-like receptor activation [152] as well as their interference with the glycosylation of ACE2 receptors, causing reductions in binding efficiency between the SARS virus S protein and ACE2 receptors [153] . By increasing the pH inside endosomes and lysosomes where SARS viruses enter cells by the process of endocytosis, the fusion of the virus membrane with the endosome membrane could be prevented or reduced, and this potentially blocks subsequent entry of viral RNA into the cell cytoplasm where replication of the virus occurs [153] . Since CQ and HCQ also have some immunomodulatory properties, such as preventing Toll-like receptor activation and antigen presentation, these drugs may also interfere with host immune activation [154] . The immunomodulatory properties of CQ and HCQ are thought to be important in reducing the over-activity of host responses that seem to worsen COVID-19

symptoms, such as excess production and release of inflammatory cytokines [155] . These immunomodulatory properties were considered important in the treatment of rheumatic diseases with CQ and HCQ [156] . In COVID-19 patient studies in France the use of HCQ suggested there was some benefit. For example, treatment with HCQ reduced viral carriage in nasopharyngeal swabs on the 6th day after starting treatment [157] . In this preliminary study on 20 patients who were treated with HCQ, 14 had negative swabs at day 6 compared to 2 of 16 controls. An analysis of the effects of CQ and HCQ in patients in 3 of 4 randomized clinical trials reported favorable treatment effects, such as duration of cough and fever, viral shedding, recovery, death [158] .

However, follow-on studies in 25 different hospitals using 1438 COVID-19 patients indicated that there were no significant differences in mortality for patients taking HCQ (± azithromycin) compared to azithromycin alone [145] . In a subsequent systematic review and analysis of 37 clinical studies involving 45,913 patients there was no significant difference in treatment efficacy between HCQ with azithromycin and control groups [159] . It is interesting to note that the use of J o u r n a l P r e -p r o o f azithromycin, an antibiotic, has no role in the treatment of viral infections, but it could be important in suppressing co-infections, such as mycoplasmas, that have been found in COVID-19 patients with severe symptomatology [143] . In addition to CQ and HCQ, colchicine, another drug with antiinflammatory properties has been used to treat COVID-19, [160] , especially in those patients where COVID-19 affects the heart [161] or in those where prevention of COVID-19 complications are needed [162] . The results, however, remain controversial and are under further study [163] .

Certain antivirals have proved useful in treating COVID-19 patients and reducing viral load.

One of the approved antivirals is Remdesivir, which selectively inhibits viral RNA-dependent RNA polymerase and has broad-spectrum antiviral activity against several viruses [145] . This antiviral drug was found to be a potent inhibitor of SARS-CoV-2 replication in human nasal and bronchial airway epithelial cells [164] . In a randomized, double-blinded, placebo-controlled, multi-centered trial Remdesivir did not significantly improve the time to clinical improvement or time to clearance of SARS-CoV-2 in severe cases of COVID-19 compared to placebo, but it did cause reductions in viral load in bronchoalveolar lavage and pulmonary infiltrates [145] . Other trials did, however, find some benefits over placebo and faster recoveries without seeing significant differences in mortality [145] . In one randomized, placebo-controlled trial containing 237 patients in China, patients with symptom durations of 10 days or less that received Remdesivir showed faster times to clinical improvement than those receiving placebo, although these differences did not reach statistical significance [165] . In another trial 584 patients with moderate COVID-19 were randomized to a 5day course of Remdesivir and had statistically significant better outcomes compared with standard care, but those randomized to a 10-day course of treatment were not statistically significantly different from controls [166] . Another example was the double-blind, randomized, placebocontrolled trial using 1062 patients who received a 200 mg loading dose of Remdesivir on day 1, followed by 100 mg daily for 9 additional days or placebo [167] . Patients who received Remdesivir were found to be more likely than those who received placebo to show clinical improvement at day J o u r n a l P r e -p r o o f Journal Pre-proof 15 (odds ratio=1.5). Estimates of mortality were 6.7% with Remdesivir and 11.9% with placebo by day 15, and 11.4% with Remdesivir and 15.2% with placebo by day 29 [167] . Other antivirals, such as Favipiravir, Lopinavir, Ribavirin and Arbidol, have been proposed as possible new antivirals to treat COVID-19 but have not been fully evaluated [168] .

Another drug that has been under consideration for the treatment of COVID-19 is ivermectin [169] . Although this drug has been used as a broad-spectrum anti-parasitic agent with antiviral activities, its clinical use in COVID-19 patients has been limited due to formulation challenges [169] . Ivermectin has been shown to have efficacy against SARS-CoV-2 virus in vitro, but standard doses used clinically did not show differences between drug and control COVID-19 patients [15, 170] .

Specific monoclonal antibodies against the SARS-CoV-2 S protein have been approved for use in treatment of COVID-19. One such therapeutic, Bamlanivimab, is a neutralizing monoclonal antibody (LY-CoV555) that targets the receptor-binding domain of the SARS-CoV-2 S protein. A Phase 2, randomized, placebo-controlled, multi-centered trial of Bamlanivimab suggested a potential benefit for outpatients with mild to moderate COVID-19; however, the study had a relatively small number of participants in each dosage arm (3 different dose levels were used) of the study. The authors reported more than a 3-log decrease in viral RNA at day 11 after receiving a single dose of the monoclonal antibody and slightly lower symptom severity scores, and the infusions lowered the subsequent hospitalization rates from 6.3% to 1.6% [171] . Another approach has been to use a cocktail of neutralizing monoclonal antibodies, such as REGN-CoV2 [172] . This mix of monoclonal antibodies reduced viral load, with a greater effect in patients whose immune response had not yet been initiated against SARS-CoV-2 or who had a high viral load at baseline and COVID-19 is no different [168] . Patients who develop humoral immunity to the SARS-CoV-2 virus and recover from COVID-19 are potential plasma donors for other COVID-19 patients. The protective and therapeutic benefits of convalescent plasma against COVID-19 are being evaluated, and this methodology is being used on an emergency basis for patients who have a severe case of COVID-19 with rapid progression [173] .

In severe cases of COVID-19 supportive care and suppression of secondary events, such as inflammation and coagulatory processes, are essential for improving survival [174] . Among the suggested supportive care approaches are oxygen (with ventilation), hydration and dielectric balance, anti-inflammatory treatments and controlling cytokine storms, anti-coagulation, nutritional interventions, along with other supportive care approaches, are collectively important [145, 146] .

Since COVID-19 is a systemic multi-organ viral disease that is frequently complicated by severe host reactions, a combination of interventions is often necessary, especially in the severe cases [175] .

As described above, the severity of ARDS and other COVID-19 pathologies are usually linked to excessive inflammation and oxidative stress, so important treatments that are directed at these processes are especially critical in severe ICU COVID-19 cases [176] . Indeed, the severity of COVID-19 appears not to be directly related to viral load, but it is instead related to inflammatory processes associated with cytokine storm and an increase in pro-inflammatory cytokines and chemokines [15, 147] . This can cause a hyper-inflammatory syndrome in COVID-19 patients that is characterized by a fulminant and fatal hypercytokinemia, ARDS, and progression to mutli-organ failure (kidney, liver, heart) [15] . Effective treatment of severe COVID-19 cases usually requires reduction of inflammation and control of thrombosis [147] . [177] , although there was no benefit for patients who were not receiving respiratory support and could be harmful in some patients [177, 178] .

A common finding in patients who die from COVID-19 is widespread thrombosis with severe endothelial injury associated with the presence of intracellular virus and disrupted cell membranes [178, 179] . Histologic analyses of pulmonary vessels in these patients revealed extensive alveolar capillary fibrin microthrombi and evidence of angiogenesis as well as diffuse intravascular coagulation and large vessel thrombosis, which are often linked to multi-system organ failure [178] .

For example, the use of heparin to control coagulation appeared to be useful for severe COVID-19

presentations [180] . Thus, anti-coagulation treatments have been used to improve survival of COVID-19 patients [146, 181] . Several alternative support supplements have also been proposed for COVID-19 patients [146, 181] , including vitamins C and D, glutathione, alpha-lipoic acid, phospholipids and a variety of plant extracts [146, [181] [182] [183] [184] [185] [186] .

The most widespread method of infectious disease prevention is mass vaccination in order to quickly acquire herd immunity (HI) in the vaccinated population. Vaccines against COVID-19 have been developed at a pace never done before in the history of mankind. Once SARS-CoV-2 was identified and sequenced in January 2020, the first mass vaccinations of a susceptible population was achieved under a national health plan starting in January 2021 [187] . The alternative to mass vaccination depends on HI, which is the resistance to the spread of an infectious disease within a population based on a high proportion of individuals having pre-existing immunity achieved as a result of previous natural infections (or previous vaccination campaigns). The HI against SARS-CoV-2 via allowing natural infections has not proved successful based on rates of hospitalization and mortality, for example in Sweden [188] . Hence, HI is most likely obtained using vaccines. The percentage of individuals in a population needed to obtain HI varies with the reproduction number,

Ro, that indicates the average number of people who will contract a contagious disease from one person with that disease. The Ro for SARS-Cov-2 is estimated at 2 to 3 [189] . The efficacy of a vaccine to immunize a population, the speed of a vaccination campaign and other factors also influence the population percentage needed for HI. The percentage calculated with these variables usually ranges between 60 to 90% of the population, and the time to achieve HI can vary from 1-2 years, depending on the size of the population and vaccination rate [190] . The different vaccines that have been used against SARS-CoV-2 make use of the injection of mRNA to produce antigenic viral proteins, viral vectors carrying non-infectious viruses with CoV-2 antigens, viral subunits, inactivated virus and also a nasal spray of live attenuated viruses [190] . Several of these vaccines have proved effective in preventing or limiting the disease, reducing hospitalizations and preventing mortalities and are currently being introduced into various populations around the world. At the time that this contribution was being prepared, it was still too soon to conclude which approach to vaccination against SARS-Cov-2 was the most successful.

ACE2 receptors and TMPRSS2 proteases are found in human oocytes, zygotes and embryos, showing the potential from early stages in conception to be infected by SARS-CoV-2

[191]. In cells collected from biopsies from human embryos in the blastocysts-stage, it has been reported the SARS-CoV-2 infection of cultured embryos by detection of the expression of the spike glycoprotein fused with green-fluorescent-protein the embryos collected [192, 193] . Those receptors needed for viral infection into these cells are present in the female reproductive tract, the embryo since early stages, and the maternal-fetal interface [194] . However, though the potential entry exist, a systematic review of pregnant women in early stages concludes that the levels of expression may be too low at the interphase to account for vertical transmission of SARS-CoV-2 at these stages J o u r n a l P r e -p r o o f [195] . Neither there is evidence of vertical transmission at advanced stages of pregnancy, except for some reports showing transplacental passage of SARS-CoV-2 and infection of the offspring showing neurological symptoms [196, 197] . Though further research is needed, to date there is no evidence that SARS-CoV-2 could impact negatively human reproduction in its early and advanced stages [198, 199] . Nevertheless, although the molecular evolution and mutation rate of SARS-CoV-2 seems to be less than for influenza or SARS-CoV-1, special attention is needed as in other emergent diseases such as Zika Virus, a single mutation was enough to increase the Zika Virus neurotropism and increase the incidence of microcephaly in the Brazil outbreaks in 2015 [200, 201] . Though there is no evidence to support frequent vertical transmission and teratogenic effects in the unborn child from infected patients, due to the increased risk of respiratory viral infections during pregnancy [202, 203] , the continuous molecular evolution of variants of SARS-CoV-2 [204] , and the adverse outcomes of pregnancy such as preterm birth, preeclampsia, intrauterine growth restriction [205] [206] [207] , there is a consensus in the scientific community that SARS-CoV-2 infection during pregnancy is worthy of special attention and further studies [208] [209] [210] .

Regarding neonates from infected mothers, most of them are not infected with SARS-CoV-2 if precautions such as avoiding aspirations from the birth canal during delivery are taken [211] . In Sweden it has been found a mildly higher rate of neonatal respiratory dysfunction (3% versus 2%), but not mortality rates (0.3-0.12%) [212] . Mothers having COVID-19 does not necessarily require cesarean surgery for delivery [213] . It is even recommended the management of the neonate that is not infected, to be next to the mother with breastfeeding, though sharing the bed is not recommended [213] . In those newborns that are infected, and test positive for a PCR reaction diagnostic test, when they are symptomatic it is common to observe lymphopenia, anemia (low hemoglobin levels) and low albumin levels, accompanied by liver and renal dysfunction [214, 215] .

In these cases, or even if they present suspected symptoms, it is recommended to transport them in a dedicated isolated incubator to quarantine in the neonatal intensive care unit (NICU), for at least 14

Journal Pre-proof days taking care of isolating their infectiveness through contention of their droplets [214] . At the NICU they need to be hemodynamically and respiratory monitored and stabilized. The only drugs that are being studied for using in those cases where the disease get severe are corticosteroids and tocilizumab to prevent cytokine storms [214] . If the neonates test positive for COVID-19, but are asymptomatic, they can spend their quarantine time at home. [214] . Psychological support of the families and healthcare workers is recommended in these situations [214] .

It has been reported that the placenta from symptomatic COVID-19 positive mothers gets infected, especially the syncytiotrophoblast cells at the materno-fetal interface of the placenta [216] . This infection can lead to severe preeclampsia and placental abruption though there is no evidence of vasculopathy, finding instead a dense macrophages infiltration [216] . The infection of the human placenta may lead to alterations in the local renin-angiotensin system, explaining the preeclampsia like outcomes during pregnancy [217] , This finding shows the potential for severe complications of pregnancy promoted by infection by SARS-CoV-2. This is quite important as it has been shown that due to severe infections of the placenta by SARS-CoV-2, there can be important impacts in neonatal outcomes, even in the absence of vertical transmission [218] .

However, as it happens with vertical transmission, severe infection of the placenta in COVID-19

infected pregnant women, is not frequently observed [218] . This is because usually there is not a In pregnant women infected with SARS-CoV-2 and mild to moderate symptoms alterations of the placenta observed at gestational weeks 40 or 41 (after birth), some showed signs of villitis, frequent maternal malperfusion, though fetal malperfusion was less frequent [221] . About 60% of these women who had mild COVID-19 during pregnancy, showed negative tests for SARS-CoV-2 and inflammation of the placenta was not found [221] . However, these findings are controversial, because in a recent cohort study with careful observation of placental alterations in COVID-19

positive pregnant women, maternal malperfusion and villitis were not the main findings [222] .

Instead the significant differences reported in this study between infected pregnant women and control cases, were fetal malperfusion (21% versus 4%), with decidual arteriopathy and inflammation, perivillous fibrin deposition (30-40% versus 1-3%), and finally fetal vessel thrombi (22% versus 1%) [222] . Another recent study, showed that in about 5% of SARS-CoV-2 positive pregnant women (9 in 198 cases), a strong correlation between trophoblast damage and placental SARS-CoV-2 infection was observed [223] . This finding might explain why there is an increment of fetal death associated with COVID-19 disease in pregnant women [223] , though some reports argue that placental infection it is a rather rare finding in SARS-CoV-2 positive women [224] . The receptors for host cell entry by SARS-CoV-2 (ACE2 and TMPRSS2) have been found in throphoblasts from placentas in the 3 rd trimester of gestation [225] . A relevant finding important for vaccination strategies, is that antibodies can be transferred from the mother to the offspring and traverse the placenta, since the 2 nd trimester of gestation [226] .

In mothers, most of the reported cases have occurred between the 2 nd and 3 rd trimester of gestation, developing a severe disease only 1% of the infected mothers [214] . In a study performed in the United Kingdom, from 1148 hospitalized pregnant women that were COVID-19 positive, 63% had symptoms [227] . The symptomatic cases had a higher risk of severe disease and admission J o u r n a l P r e -p r o o f to Intensive Care Unit. They were mostly overweight or obese as well [227] . It was estimated an incidence of hospitalizations of symptomatic COVID-19 pregnancies of 2 in 1000 maternities and an incidence of 1.2 in 1000 maternities for asymptomatic COVID-19 pregnancies [227] . The risk factors predicting illness severity in a study performed in the United States were age (30-39), obesity, healthcare occupation, black and non-hispanic ethnicity, and preexisting diseases such as cardiovascular diseases, diabetes, hypertension and chronic lung diseases [228] . Pregnant women should be vaccinated as soon as they can because of their higher risk and concerns for potential future COVID-19 infections [229] . Any person can conceive after being vaccinated waiting not longer than one or two days. The main issue about vaccination in pregnant women is to protect the mother from being infected by SARS-CoV-2. Regarding conferring immunity to offspring, transfer will occur especially since the 2 nd trimester of gestation because of the maternal-fetal barrier, though the main purpose of vaccination during pregnancy is the mother and not the offspring [230, 231] . It has been shown that the breast milk of vaccinated mothers contains SARS-CoV-2 specific antibodies. Vaccination during breastfeeding is also encouraged [232] . The effects of SARS-CoV-2 infection in human reproduction after conception are summarized in Table 1 .

The Zika virus (ZIKV) is an RNA flavivirus that belongs to the Arbovirus genre, and the family Flaviviridae [233, 234] . It is phylogenetically quite close to dengue virus, yellow fever virus, West Nile fever virus, and the Japanese encephalitis virus [233] . It is a single-stranded RNA virus with two different evolutionary lineages: the Asian lineage and the African lineage [235] [236] [237] . The to infect humans [235] [236] [237] . The virus is transmitted mainly through female mosquito bites, especially from the species Aedes aegypti and Aedes albopictus. Other methods of Zika disease transmission that are less frequent are: mother to neonate, sexual, transfusions, transplants, and by rare laboratory accidents [81, [238] [239] [240] .

The ZIKV was not considered as a widespread pathogen capable of causing considerable outbreaks and sequels until a recent large outbreak in Brazil in 2015. In Brazil the ZIKV was also associated with microcephaly and Guillain-Barré syndrome. Two distinct manifestations of ZIKV infections are sexual and trans-placental transmissions associated with neurological sequels such as the Guillain-Barré syndrome and microcephaly [241] . Similar with most arboviruses, the ZIKV participates in a complex cycle of transmission between insects and vertebrates. After the flaviviruses are transmitted via female mosquito bites, they initially replicate in the immune dendritic cells next to the skin, and later they inhabit the lymphatic ganglia. Finally, they spread systemically throughout the whole body through the blood [242] .

Since its appearance in Micronesia, ZIKV has spread around the world, and it is attributed to ZIKV is highly homologous to dengue virus (60% homology) [248] . The ZIKV genome encodes three structural proteins, the capsid (C), envelope (E), and membrane (prM) proteins. The genome also encodes for seven non-structural proteins (nsps proteins), which are important for virus replication, protein processing, and countering host antiviral immune responses. Following cell binding and endocytosis, the Zika viral RNA is uncoated, released, and translated into a single polyprotein in the cytoplasm [249] . This polyprotein is cleaved into mature viral proteins by nsps and cellular proteases. These events occur in association with the endoplasmic reticulum (ER),

where the viral components are packaged by the C protein, while they acquire their lipid bilayer envelope from the ER. There is subsequent processing, consisting of glycosylation and cleavage of prM by a host furin protease, which appears to be necessary to release the mature virions from the infected cells. The E-protein seems to be vital for the ZIKV life-cycle, and it is critical for viral entry into host cells, membrane fusion, and virus assembly [250] . Some of the epitopes designed for detection antibodies and also putative antiviral compounds have been directed towards the E protein and some of the structural proteins and nsps proteins [241] .

Zika virus infections are usually acute and self-limited, and the transmission of ZIKV can be vector or non-vector borne. The life cycle in vector-borne transmissions (the most frequently J o u r n a l P r e -p r o o f observed) starts with virus acquisition by a mosquito during a blood meal. The virus then replicates inside the mosquito until it reaches its salivary gland, where it can be eventually part of the injected fluid that flows into a new host during a blood meal [249] . The human skin in the region of the bite is the first site of viral replication in the new host. There is a preference for replication in fibroblasts, keratinocytes and immature dendritic cells. From the inoculation site, ZIKV can travel through lymphatic vessels to lymphatic ganglia, and finally it can be spread as a blood-borne infection throughout the entire host organism where it can produce viremia [251] . The ZIKV incubation period can vary between 3 and 12 days, and this is followed by a consolidated illness state where the presentation can differ between asymptomatic (80% of the cases) to a moderate dengue-like fever presentation (20% of the cases). The virus can be found in the blood of the patients during this period [252] .

The symptoms of most ZIKV infections are fever, macular or papular rash, conjunctivitis (red eyes), arthralgia, headache, and myalgia, sometimes with retro-orbital pain [252] . These symptoms usually last between 4 and 7 days [238, 253] . Sometimes it is difficult to differentiate the symptoms of ZIKV from other infectious diseases caused by other arboviruses, especially dengue and chikungunya. The presence of exanthema (pruriginous maculopapular rash) starting in the face and/or trunk suggests a ZIKV infection [254, 255] .

During infections the Zika virus can be found in urine, saliva, and other body secretions weeks after the initiation of the infection, indicating that the ZIKV infections are systemic [240] . It is epidemiologically relevant that in men the virus is attracted to testicular tissue (positive tropism) and can be excreted in semen for months after the infection was initiated, making ZIKV infections also sexually transmitted diseases [256] . Moreover, ZIKV can have complications with sequelae like the Guillain-Barré syndrome and hemorrhagic symptoms [241] . Guillain-Barré syndrome is an autoimmune disease of the nerves that starts with weakness and tingling to later cause a flaccid paralysis of the body. The temporal coincidence of the incidence between the Guillain-Barré J o u r n a l P r e -p r o o f Journal Pre-proof syndrome with Zika virus outbreaks has been essential in linking these diseases. Most of the ZIKV-Guillain-Barré syndrome patients also had elevated levels of IgM antibodies against Zika virus and experienced rapid progression of the neurological symptoms [257] . The hemorrhagic complications of ZIKV are usually mild, though in some cases they can be severe [258] .

The outbreaks reported in French Polynesia between 2013 and 2014 and in Brazil in 2015

were important in establishing the association between Zika virus infection, Guillain-Barré Syndrome, and microcephaly. Other less frequent complications that can happen, usually in less than 1% of ZIKV patients, and can include: transverse myelitis, meningoencephalitis, myocarditis, and thrombocytopenic purpura [254, 259, 260] .

The entry of the ZIKV into host cells is not fully understood, but phosphatidyl receptors (TIM-1, TIM-4, AXL, and Tyro-3) seem to be quite important [251] . AXL (Tyrosine-protein kinase receptor UFO anexelecto) , seems to be the receptor linked to ZIKV neurotropism, and TIM- II may slow down the viral replication and infection of ZIKV [251] . The small-membraneassociated-interferon-induced transmembrane proteins (IFITMs) that inhibit the replication of many viruses are also quite effective against ZIKV replication [263] . To defend against the host immune system ZIKV has developed mechanisms that inhibit host responses, such as methylation of the viral genome and inactivation of interferon signaling through the NS viral proteins [249] . Recent studies have identified some of the host proteins and enzymes related to the ER that are needed for efficient viral replication in host cells [264] .

The techniques used for the diagnosis of ZIKV infections received a boost in 2016, when the USA declared a public health emergency related to an outbreak of ZIKV in that country [265, 266] .

Several molecular assays and serological assays were developed during the following two years [267] . The recommended diagnostic techniques, molecular or serological, vary during the course of whereas IgG antibodies appear 3 days after IgM antibodies and remain increased for many years [268] . There is also a possibility of cross-reaction with other Flaviviridae viruses [269] . Because of this, this later assay should be combined with other diagnostic tests to distinguish between other viral infections, such as dengue, and also bacterial infections.

There is no specific treatment for ZIKV infections, and specific antiviral drugs are not available. The recommendations for therapy are usually symptomatic and support treatments [270] .

Prevention and control and avoiding mosquito bites are the main protective measures to avoid ZIKV infection (use of mosquito repellent, adequate clothes, mosquito nets, etc.). Vector control, blood and tissue bank tests, and prevention of sexual and vertical transmission are also useful for reinforcement of protective policies. In those countries where there is a possibility of vertical transmission from mother to fetus, community measures to control mosquitoes and eliminate mosquito reservoirs are needed [238] . There is no vaccine against the ZIKV to prevent the disease, J o u r n a l P r e -p r o o f Journal Pre-proof though some vaccines are currently under development and being tested [270] . Some advances in antiviral therapeutics and vaccines are underway, but they are still in early phases of development.

Due to the similarity with Dengue virus, there have been proposals of designing a unified ZIKV and Dengue virus vaccine, or to share resources to get both vaccines [248] .

The infection with ZIKV during any stage of pregnancy can cause birth defects, though the adverse outcomes in the offspring have a higher risk at ZIKV infections during the early stages of pregnancy. The estimated rate of mother-offspring transmission can vary between 7 and 26%

depending on the methodology of study [271] . hypertonia and signs of extrapyramidal syndrome involvement [272] . Another set of observations that helps to explain these symptoms are anomalies of the corpus callosum (71-100%) and of the posterior fossa (21-82%). Extra-neurological signs observed were intrauterine growth restriction (14%), placentomegaly, hepatitis and anemia [271] . The high neurological in the offspring is due to the positive neurotropism of the ZIKV, once it goes through the placental barrier [273] . The neurotropism is also present in ZIKV infected adults, that can develop a Guillain-Barre syndrome J o u r n a l P r e -p r o o f Journal Pre-proof [274] . The molecular basis of this neurotropism has been related to the expression of the Axl gene, which is a Tyrosin Protein-Kinase receptor that has been found in glial cells [275] . Glial activation and proliferation through Toll-like receptors (essential for the innate immune responses), is activated resulting in apoptosis, cell death and inflammation in the nervous system [276] . As a result there is cell-cycle arrest and the developing neurons die [277] . This is important to know, as a good therapeutic strategy with pregnant women infected with ZIKV to diminish the risks of fetal development is to inhibit the interaction of ZIKV with its host cell receptors (besides prevention through vaccination and diminishing Aedes Agypti contaminated populations) [278] .

Regarding newborns, those that acquire ZIKV infection perinatally or after delivery can have symptoms like maculopapular rash, conjunctivitis, arthralgia (joint pain) and fever, but CZS is rare [279, 280] . ZIKV can be found in breast milk in ZIKV infected women [281] . Even though there is controversial evidence of newborns infections with ZIKV through breast milk [282] , the advantages of breastfeeding surpasses the risk of acquiring ZIKV disease by the babies and breastfeeding by infected mothers is encouraged [283] . Most babies that acquire ZIKV infection seem to be asymptomatic or experience a mild disease like it is observed in adults. However, the information regarding long term outcomes of babies infected with ZIKV is still limited and further research is needed.

Villous immaturity is the main histopathological finding among ZIKV infected women, although placentas without any abnormalities have been also frequently observed [284] . Infections during the 3 rd trimester are characterized by syncytial and fetal macrophages hyperplasia (Hofbauer cells) [284] . ZIKV from infected mothers, have to cross a series of barriers in order to reach the brain cells from the offspring. The maternal-fetal barrier has a series of multicellular layers between the fetus and the mother that results mostly from the differentiation of cytotrophoblasts being surrounding all the previous structures [285] . There are many junctional structures among cells that can be disrupted during inflammation [286] . The syncytiotrophoblast layer of the villus branch seems to be the most resistant layer of the barrier [287] . Once it penetrates this layer, ZIKV is able to infect the rest of the cells, especially macrophages (like Hofbauer cells) and trophoblast cells, disrupting their junctions [288, 289] . It has been shown that ZIKV can pass through the placental barrier, reducing the expression of occludine and ZO-1 (tight junction proteins), facilitating a paracellular passage through human placenta trophoblast cells [290] . The blood-brain barrier from the offspring, can be infected by ZIKV, and a transcytosis passage of ZIKV has been proposed

[290]

Regarding mothers and ZIKV infection, the symptoms in adults have already been considered. Prevention of ZIKV infection besides protection against mosquito bites and vaccines (on trial) [291] , considers waiting for at least two months in ZIKV infected women and up to six months in infected men for clearance of the ZIKV from the body, before having sexual relationships [292] . Once the virus is cleared-up from the body, there is no evidence that future pregnancies can be compromised. As ZIKV infection confers long lasting immunity this is some sort of natural vaccination by getting the disease though it has been shown there is a decline of immunity through the years, especially in adults [293] . There is evidence that having ZIKV infection increases the risk of having dengue disease [294] . There are cross-reaction effects of infections by similar viruses like dengue. These effects and consequences are currently under study [295] . As it has been mentioned before, ZIKV can be found in breast milk, though there is a broad consensus that breastfeeding by infected mothers should continue because the benefits are higher J o u r n a l P r e -p r o o f Journal Pre-proof than the risks [283] . The effects of ZIKV infection in human reproduction after conception are summarized in Table 2 . pneumoniae) encode approximately 400-600 proteins, compared to about 4,000 encoded by the genome of E. coli [296] . Mycoplasma genomes can be composed of single-stranded RNA or double-stranded DNA. As intracellular infections, they have an osmotrophic form of nutrition, and they use a replication disk for their cell division [296] . They are extremely common in all forms of life, living as symbiotic or infectious intracellular forms. Importantly, mycoplasmas still maintain all of the essential genes for their replication, transcription, and translation as well as the minimal number of energy metabolism genes needed for their intracellular, parasitic modes of life. Thus, they can survive, grow and replicate with a core number of slightly less than 400 essential genes [298] . controversial, because they have also been found as part of the normal flora of healthy individuals located at superficial sites in the urinary, genital and respiratory tracts. They are rarely found in the blood and the internal organs and tissues in normal, non-symptomatic humans [300, 301] . The adherence of mycoplasmas to specific tissue and cell surfaces is a crucial step in the establishment of pathogenic infections, and pathogenic mycoplasmas possess specialized structures that permit targeted cell attachment to specific host cells and host cell receptors. For example, M.

pneumoniae, which is commonly found in cases of atypical childhood and adult pneumonia, requires a network of interactive adhesion molecules and accessory proteins for its adherence to host lung epithelial cells [301, 303] . The adhesion molecules must cluster cytoadherence-related J o u r n a l P r e -p r o o f accessory proteins where specific mycoplasma organelles make cell contact. These adherence proteins appear to function together and comprise a primitive mycoplasma membrane adhesion structure [2, [300] [301] [302] 309] .

Mycoplasmas are known to be able to adapt quickly to new microenvironments, especially intracellular environments [303, 310] . This adaptation is an important element in mycoplasma pathogenicity, and it can be attributed to their varying genomic structures and abilities to undergo rapid change [301, 302, 310] . [310, 311] . The result is that the changes in mycoplasma surface components can influence cell and tissue colonization and penetration of mucosal barriers, which are, in turn, directly related to mycoplasma pathogenicity [300, 311] .

As mentioned, mycoplasmas have small and unique genomes that contain repetitive and other elements that contribute to the variability in surface antigenic structures [310, 311] . For example, the genome of M. genitalium was recently sequenced and found to encode a number of identifiable membrane proteins as well as membrane glycolipoproteins whose sequences do not resemble previously sequenced genes [312] . One recently discovered example in M. genitalium is the repeat fragments of a gene encoding a 140 kDa adhesion lipoprotein (MgPa), and interestingly, this lipoprotein was subsequently localized to the tips of mycoplasma protrusions where it facilitates cell attachment and penetration [313] .

There are also mycoplasma repetitive sequence elements that are variably transcribed but do not appear to encode surface-expressed mycoplasma proteins. Recombination of these repetitive elements with other genes and their ultimate expression in different mycoplasma strains may generate unique structures that explain the appearance of the polymorphisms within the genes and their encoded surface proteins. Thus the repetitive elements found in the M. genitalium genome may provide a reservoir of available protein sequences that could combine and contribute to the variability of antigenic structures expressed by mycoplasmas. By changing the adhesive properties found in pathogenic mycoplasmas this could affect the ability of mycoplasmas to penetrate into specific tissues and organs and cause various symptoms and illnesses [314] .

associated with the expression of specific surface markers of lymphocyte activation. This was seen in lymphocytes (both CD4+ and CD8+ T lymphocytes) from healthy human donors as well as in lymphocytes from HIV-1-infected subjects at different stages of AIDS progression [319] . This example indicates that pathogenic mycoplasmas have evolved with the ability to rapidly modulate and interfere with host responses in different ways.

Another property of pathogenic mycoplasma interference in host responses is the ability of some species to modify the secretion of immune-modulating substances. The secretion of immunemodulating substances stimulated by pathogenic Mycoplasma species is an important facet of mycoplasma immune modulation [315] . In the case of the mycoplasma human pathogen M.

fermentans, a secreted lipoprotein was found that stimulated the induction of several monocyte cytokines and chemokines [320] . Another example of a secreted mycoplasma immunomodulatory lipoprotein is spiralin, which can stimulate the in vitro proliferation of human peripheral blood mononuclear cells and murine splenocytes. Eventually this results in the secretion of several proinflammatory cytokines, such as TNFα, IL-1 and IL-6. In addition, spiralin can also induce the maturation of murine B-cells. The spiralin-mediated stimulation of cytokine secretion may be similar to other immune-modulating lipoproteins secreted by other pathogenic bacteria [321] . The stimulation of various cytokines by pathogenic mycoplasmas is an important property that can contribute significantly to patient morbidity [316] .

Mycoplasmas also evade immune recognition and destruction due to their ability to undergo rapid surface antigenic variations [315] . Mycoplasmas have slow intracellular growth rates compared to other bacteria, allowing them to be targeted by host immune surveillance systems.

However, they can escape host surveillance by rapidly altering their cell surface antigenic structures. This along with the ability to alter host immune responses allows pathogenic mycoplasmas to evade host surveillance [315] . Mycoplasmas, especially intracellular mycoplasmas, grow slowly compared to extracellular bacteria that use the speed of their division to outpace and J o u r n a l P r e -p r o o f evade immune responses by overwhelming host defensive abilities, so mycoplasmas have developed other mechanisms to evade host surveillance. Their slow intracellular growth rates may also help explain the chronic nature of mycoplasmal infections. Slow growth and other properties of mycoplasmas have forced them to evolve with properties other than rapid growth to allow them to hide and evade host surveillance systems [300, 302] .

The abilities of pathogenic mycoplasmas to adapt to unique host tissue and cellular microenvironments are usually accompanied by changes in surface adhesion receptors for cellbinding and entry as well as structural protein changes that mimic host antigenic structures. This latter property allows mycoplasmas to 'hide' from host surveillance. One of the ways that this occurs is by the property of antigen 'mimicry,' seen during chronic pathogenic mycoplasma infections, and driven by quickly changing the size, structural diversity and expression of cell adhesion antigens. For example, the divergence of variable surface antigens mentioned previously can affect the adherence properties of mycoplasmas and enhance their abilities to evade foreign protein recognition by host immune systems. This adaptive ability helps mycoplasmas to survive undetected in their human hosts, but this is only one example of the abilities of pathogenic mycoplasmas to achieve survival and at the same time change their pathogenic properties [300, 301, 303, 310, 315] .

There are various methods that pathogenic mycoplasmas use to overcome host mechanisms that attempt to limit their ability to colonize cells and tissues. Moreover, one strategy appears to rely on changing structural proteins and glycoproteins while separately weakening host antimicrobial mechanisms. This can result in changes that cause systemic results that come at the detriment of the host. For example, the stimulation of host inflammatory responses in order to kill or incapacitate a microbial invader can result in the release of inflammatory cytokines that also cause severe host symptoms. In the case of pathogenic mycoplasma infections, the severity of host symptoms closely parallels the elevated expression of inflammatory cytokines [310, 315, 316] .

Other possible virulence mechanisms are implicated in the pathogenesis of mycoplasmas [301, 322] . One example is the intracellular competition for nutrients and metabolites. This competition between mycoplasmas and their host cells can deplete biosynthetic precursors and disrupt metabolic and synthetic pathways that weakens the host and its ability to respond the invader mycoplasmas. Although mycoplasmas can stimulate host enzymes and other proteins, most mycoplasmas can synthesize and secrete many of their own enzymes, such as lipases, proteases, nucleases and other enzymes. These mycoplasma enzymes can disrupt and interfere with host substrates, products and metabolic cycles [301, 310] . Mycoplasmas also have the capacity to stimulate the generation of cellular-damaging molecules, such as hydrogen peroxide and superoxide radicals, that can damage host cellular membranes and other structures [322] . There are other possible ways that pathogenic mycoplasmas can be involved in damaging host cellular structures and normal cellular processes, such as direct membrane-membrane interactions found in cell adhesion, membrane fusion, vacuolization, and release of toxins or cytopathic molecules from cells [300, 301, 322] . The goal remains for pathogenic mycoplasmas to hide and survive, not to kill their host. However, in the process host cells can die. For example, one property of pathogenic mycoplasmas is the ability to initiate programmed cell death or apoptosis. This can be useful, for example, if the host cells are involved in immune responses [322] . Some mycoplasmas can induce or enhance apoptosis of peripheral mononuclear cells. In this case, the human pathogen Mycoplasma penetrans can program for an endonuclease (p40) that has been identified as a pathogenic determinant [323] . Pathogenic mycoplasma-released nucleases may also be involved in secondary necrosis, and this has been documented in some progressive mycoplasmal infections [324] . Other pathogenic properties of mycoplasmas are mediated by unknown or partially known mycoplasma-encoded molecules [325] .

In addition to stimulating cell and organ death, pathogenic mycoplasmas can also release growth inhibitory molecules into their surroundings. For example, the enzyme arginine deaminase J o u r n a l P r e -p r o o f is an example of a growth-inhibitory enzyme derived from certain mycoplasmas that inhibits the

inducing the morphologic features of dying cells, including the type of DNA fragmentation pattern seen during apoptosis [326, 327] . This enzyme has been followed in patients with communityacquired pneumonia as a possible marker for M. pneumoniae infections [328] .

Pathogenic mycoplasmas can also release toxins that directly damage cells or activate innate host response systems [329, 330] . vascular occlusion has been reported for heart, lung, kidney, brain and other organs, but this is usually only seen in the most pathogenic mycoplasma infections [329, 330, [333] [334] [335] .

Although mycoplasmas in humans have been described in the literature since the 1930s, it has been only recently that they have been shown to play a pathogenic role in many illnesses and diseases, from pneumonia to sexually transmitted diseases [305, 308] as well as in several chronic illnesses of unknown origin [304] . The evidence that Mycoplasma species are involved in the pathogenesis of certain diseases and chronic illnesses has been based mainly on the positive responses of most patients to therapies directed specifically at intracellular mycoplasmas in patients who are mycoplasma-positive [300, 304, 307] . Using anti-microbial and integrative treatments pathogenic Mycoplasma species infections have been suppressed slowly, resulting in gradual reductions in morbidity, but this is not seen in every patient [300] . Even if mycoplasmas are not currently considered a cause for specific illnesses, they do appear to be important in the inception, progression, morbidity and relapse of several chronic illnesses [300, 301, 304, 307] . Often this can also be due to the important part they can play as co-infections [300, 336, 337] . [300, 301, 304, 307] . In these illnesses and diseases mycoplasmas might be present initially as superficial flora, such as in the oral and urogenital cavities; however, they are not thought to be pathogenic at these superficial sites. When they penetrate into body fluids, blood and tissues, they are capable of intracellular colonization of internal tissues and organs, and it is at this point that they can slowly exert their full pathogenic properties [300, 304, 336] . In some cases this might not be fully apparent until an appropriate mixture of co-infections, including mycoplasmas, is fully expressed [143, 300, 337] . [300] . Non-amplified DNA hybridization methods have also been used successfully in a few studies, for example for M. fermentans sequences [339] , but in general these test formats are not in routine use due to the complex nature of the tests, their reliability and the requirement for sufficient numbers of microorganisms for a positive result [339] .

Prevention of Mycoplasma species infections has been difficult to achieve. Most mycoplasma prevention approaches have depended on health maintenance rather than more specific approaches, such as vaccinations [340] . Mycoplasma vaccines have been under development for a few Mycoplasma species, the most common being M. pneumoniae [341] . In a small study a vaccine against inactivated M. pneumoniae was partially successful against challenge with viable M.

pneumoniae. A majority of participants developed growth-inhibiting antibodies and only one of the volunteers who responded to the vaccine became ill; whereas most of the participants that did not respond to the vaccine became ill with respiratory tract disease [341] . Various studies have shown that patients can develop cellular responses to mycoplasma antigens [342] . Indeed, cellular responses against mycoplasma antigens were shown to be durable in patients with M. pneumoniae J o u r n a l P r e -p r o o f infections [343] . Cellular immunity to mycoplasmas can develop during pulmonary mycoplasmal infections, and this is thought to reduce the severity of lung inflammation and course of the disease [344] . However, overall the development of mycoplasma vaccines compared to other bacterial infections has proved to be disappointing. Future developments will likely focus on the development of vaccines that reduce morbidity and secondary complications [345] .

The most dangerous species for the offspring are Mycoplasma hominis (MH), Ureaplama ureatylicum (UU), and Ureaplasma parvum (UP). Ureaplasma species are being increasingly recognized as pathogens raising prenatal, perinatal and postnatal morbidity [346] . UU is part of the lower urogenital tract flora, but in occasions ascends and cause bacterial vaginosis, chorioamnionitis increasing the adverse outcomes of pregnancy such as preterm birth [346] . Several reports agree that UU leads to infection of the chorioamnion which associates with premature spontaneous labor and delivery [347] [348] [349] . It plays an important role in perinatal and postnatal morbidities increasing bronchopulmonary dysplasia, neonatal sepsis and meningitis [346] . Though reports in the pathogenesis of bronchopulmonary dysplasia in the offspring were initially controversial, most of the evidence is consistent with a role of UU in the pathogenesis of this disease [350] [351] [352] . This can lead to prolonged mechanical ventilation and certain chronic lung diseases in neonates with premature birth [353] [354] [355] . Systemic neonatal infection as sepsis has also been reported for this pathogen [356] . It has been debated if UU infection can lead to central nervous system infections in neonates showing as meningitis [357] . All this can lead to an increment in morbidity and long-term hospitalization in low-weight birth newborns [358] . The diagnostic and treatment of UU infections can be challenging because it can be normally found in the absence of pathologies and there is a lack of diagnostic tests [346, 359] . Everything reported for J o u r n a l P r e -p r o o f UU has also been reported for MH, though the rate of spontaneous abortions seems to be higher with MH [360, 361] . Though these reports show that UU and MH can have adverse outcomes by themselves, UU and MH infections are also frequently associated [362, 363] . They can lead together to most of the pathologies with UU or MH alone and exacerbate them [364] . Coinfection with UU and MH can lead to funisitis (inflammation of the umbilical stump) [365] . They also impact in the neonates and they have been found in neonatal blood, cerebrospinal fluid or tissues such as lungs. It also faces the challenge of appropriate diagnostic and treatment [366] . When and how should be the treatment to reduce the incidence of adverse outcomes in pregnancy and neonates, remains unclear [366] . It is being under study the higher risk to get these pathogens during in-vitro fertilization procedures [367] . In neonates and newborns, Mycoplasma genitalium (MG). is also a cause of usually milder diseases in the neonate, from the same sort as those found with UU and MH [368] .

MG seems to be more important as a possible cause of infertility promoting endometritis, cervicitis and salpingitis in infected women [368] . It is being under study its potential to enhance HIV transmission [368] . UP has also been associated with preterm birth and an increment of mortality in newborns [369] , though most of the studies have been centered in UU and MH.

Mollicutes is a class including simplest bacteria that cause infection in pregnant women. The most usual findings by Mollicute infections in the placenta is chorioamnionitis, with the presence of the pathogens in fetal membranes and fluids (chorion, amnios, and amniotic fluid) [370] .

Chorioamnionitis is an acute inflammation of the placenta membranes and chorion, most commonly due to ascending polymicrobial infection from the lower urogenital tract, partially characterized by a neutrophil infiltration in the amnios and subchorion of the infected placentas that are observed in preterm delivery [371] . It is important to distinguish it because not all chorioamnionitis are clinically symptomatic and it might be quite difficult to obtain a successful culture of the infecting J o u r n a l P r e -p r o o f

Mollicutes. In several cases it can be extended to the umbilical cord as funisitis with leukocyte infiltration of the umbilical vessel or the Wharton's jelly [372] . Chorioamnionitis by Mollicutes can occur without rupture of the placenta [349] . It has been established that 65% of them are polymicrobial and from those, almost half are because of UU, MH and Mollicutes infections [373, 374] . The starting point is usually the flora present in the lower urogenital tract that ascends infecting the uterus, placenta and fetus. This condition happens in up to 2% of births in the USA, being an important cause of premature labor and premature rupture of membranes [370] .

Ureaplasmas are the most frequent agents causing chorioamnionitis and the adverse outcomes of pregnancy reported above. The molecular basis of its pathogenesis and why some can go up from the lower urogenital tract is currently being unraveled. Most of the evidence so far, indicates that the Major Band Antigen (MBA, a surface-exposed lipoprotein), is a major player in the pathogenesis of Ureaplasma species for causing chorioamnionitis, in fact is being considered a predicted virulence factor of the Ureaplasma species [375] . The molecular reason behind the pathogenesis, seems to be that certain antigenic variation at the level of MBA makes Ureaplasmas able to avoid immune recognition in the host, causing chronic infections and colonization of the upper urogenital tract [375] . Variations in the size of the MBA lipoprotein, modulates the host immune response [376] . MBAs from different ureaplasma species are different and respond to different antibodies as well [377] . In HeLa cells in culture, it has been observed that Ureaplasmas enter the cells through clathrin-mediated endocytosis after binding of the pathogen by sulfoglycolipids membrane receptors [378] . Later it remains in the perinuclear region being secreted through exosomes. It is thought that this mechanism could help them to avoid the immune responses [379] .

The fetal complications of chorioamnionitis are fetal death, neonatal sepsis and fetal inflammatory response syndrome with funisitis and chorionic vasculitis (FIRS, fetal counterpart of the systemic inflammatory response syndrome or SIRS) [380] . During FIRS, which is the fetal J o u r n a l P r e -p r o o f immune response to infection there is release of several pro-inflammatory mediators such as cytokines and chemokines like interleukin 6, TNF-, C-reactive protein, and matrix metalloproteinases [381] . FIRS-associated fetal immune response leads to responses that vary through preterm labor to perinatal death, being associated with multi-systemic failure in newborns (especially those preterm). The multi-systemic failure includes chronic lung disease, periventricular leukomalacia and cerebral palsy [382, 383] .

The neonatal complications of chorioamnionitis are seen at or shortly after birth. These are perinatal death, asphyxia, sepsis, and neurological complications such as intraventricular hemorrhage, white matter damage in the encephalus and cerebral palsy [384, 385] . These outcomes are worst in preterm newborns [386] .

The clinical findings in the mother that suggest chorioamnionitis are fever, sensitivity to pain in the fundus of the uterus, maternal and fetal tachycardia (more than 100 bpm and 160 bpm respectively), and purulent or abnormal amniotic fluid [387, 388] . Mollicutes can be isolated from the amniotic fluid in pregnancies with preterm birth, even without signs of clinical chorioamnionitis, but with histological findings [348] . From the clinical symptoms, though unspecific, maternal fever is the most important sign being present in 95-100% of the cases [389] .

In women with prolonged labor and epidural anesthesia, the so-called epidural fever is often found [390] . Maternal fetal tachycardia is the second common clinical finding occurring up to 80-70% of the cases. The combination of fever plus tachycardia strongly suggests intrauterine infections such as chorioamnionitis [389] . Changes in pain sensitivity in the uterus and amniotic fluid odor are both subjective and can be distinguished well only in up to 25% of the cases [389] . Subclinical chorioamnionitis can also be found and have their manifestation through preterm labor or premature rupture of the membranes [389] . Clinical diagnosis of chorioamnionitis solely, should be considered J o u r n a l P r e -p r o o f Journal Pre-proof when accessing to the amniotic fluid or placenta is not possible, as they are invasive studies [391] .

As mentioned above, fever, tachycardia and a weaker 3 rd sign (uterine pain, abnormal amniotic fluid), are needed to have a very strong prediction of chorioamnionitis based solely on clinics [389] .

When the clinical diagnosis is not clear, laboratory tests should be done if they can be performed with the patient. Maternal leukocytosis can be found in 70-90% of chorioamnionitis but it has to be accompanied with other of the reported signs of chorioamnionitis [389] . Other blood tests are being under discussion. The amniotic fluid testing obtained by amniocenteses is quite reliable but it can last up to 3 days to confirm the diagnosis. It is also limited because it is an invasive method [389, 391] .

Not all chorioamnionitis are produced by Mollicutes, there are other pathogens that might produce it, even with other ways of access to the chorioamnios like the blood [388] . However, addressing Mollicutes actions regards with the fact of their high frequency, their association with reemergent disease in some parts of the world, and their difficulty in diagnosis and treatment [389] .

The maternal complications related to chorioamnionitis are: increased risk for cesarean delivery, endomyometritis, wound infection, pelvic abscess, bacteriemia and hemorrhage after delivery [392] . When there is premature rupture of membranes, chorioamnionitis has to be suspected because it is major cause of that adverse outcome of pregnancy [372] .

The management of chorioamnionitis from offspring, interphase and mother include antibiotics and supportive measures. The antibiotic therapy should be done with broad spectrum antibiotics, and initiated as soon as possible (intrapartum), in order to prevent maternal, interphase and fetal complications [387] . Of special interest is their administration when there is premature rupture of the membranes as this adverse outcome of pregnancy is usually indicative of chorioamnionitis [372] . Antibiotics also reduce the degree of chorioamnionitis, neonatal sepsis, being able to prolong the gestational time and expected time-of-delivery in those women who are not in labor [393] . There is no consensus regarding the best antibiotic therapy because it will J o u r n a l P r e -p r o o f Journal Pre-proof depend on the main pathogens found. The most used have been intravenous ampicillin and clindamycin or macrolides (especially erythromycin) for anaerobic coverage, usually lasting 7-10 days [394] . This treatment should continue with one intravenous dose more after delivery [389] .

Oral routes after delivery can be given as well [395] . Steps to develop an universal treatment of chorioamnionitis after knowing its cause, are being currently undertaken [396] . The use of antipyretics is encouraged, especially during the intrapartum period, as the high fever in the mother can yield to fetal acidosis or neonatal encephalopathies [397] . It might also reduce fetal tachycardia [389] . If there is premature rupture of membranes, induction of labor and delivery it is recommended after 34-37 gestational weeks to avoid more severe adverse outcomes and complications [398] . The effects of Mollicutes infection in human reproduction after conception are summarized in Table 3 . [402, 403] . Ureaplasmas are moderately susceptible to macrolides [403, 404] . Some Mycoplasma species, such as M. hominis and Ureaplasma urealyticum, are generally more resistant to tetracyclines [405, 406] , and some M. hominis strains have been shown to be quinolone-resistant [407] .

Treatment of pathogenic mycoplasma infections with antibiotics generally involves daily or pulsed treatment. For example, every-other-day administration at the maximum dose recommended for a particular antibiotic has been successfully used to suppress mycoplasma infections [340, 408] .

The rationale of pulsed treatment is that mycoplasmal proliferation is often cyclic, and thus some organizations recommend every-other-day antibiotic regimens [300] . In either case long-term treatment is often required, even as much as 6-12 months, due to the slow growth rates of mycoplasmas and their relative insensitivities to various treatments [300] .

Another consideration is the age of the patient. For example, macrolides might be considered as first line therapy for young children with pathogenic mycoplasmal infections due to the potential side effects of tetracyclines and quinolones in young children [409] . Some adverse effects, such as staining of developing teeth in children under the age of eight with tetracyclines, have not been a problem with antibiotics like doxycycline, and in some cases low-dose doxycycline has been used to treat children with bacterial infections without incident [410] .

Antibiotic resistance can occur during treatment of pathogenic mycoplasmas [411] . This is exemplified by the shifting minimum inhibitory dose concentrations required to treat certain mycoplasma infections with antibiotics; for example, the treatment of M. genitalium infections with oral tetracyclines [412] . To overcome this problem, increasing antibiotic dose levels or shifting to a different antibiotic regimen have been utilized [300] . Another problem has been the appearance of Jarisch-Herxheimer reactions (J-H reactions) [300, 413] . These are observed as temporary increases in the severity of signs and symptoms, and J-H reactions generally involve fevers, chills, muscle aches, fatigue, skin rashes, pain and other signs and symptoms related to cytokine release [413] .

There are some rather simple methods to reduce the severity of some J-H reactions, and their appearance with antimicrobial treatments is thought to be due to the release of mycoplasma particles and fragments and subsequent host response and cytokine release [300] . Some feel that strong J-H reactions suggests efficacy of treatment, but this is not necessarily an indication of treatment failure or success [300] . Conventional use of antibiotics suggests using only limited treatment times, but limited treatment times fail to resolve mycoplasma infections in many chronic illnesses [307, 408, 409] . Since most mycoplasmas are slow-growing, cyclic, and fastidious, they are less sensitive, in general, to antibiotics compared to extracellular bacteria [300, 414] .

Host immune responses may also be essential in killing survivor mycoplasmas that resist antimicrobial treatments. Variant microorganisms can resist host surveillance by alteration or suppression of host responses [300, 301, 310] . Alternatively, mycoplasmas could go into non-growth phases where they are insensitive to therapies like antibiotics that target bacterial metabolism [415] .

There are a variety of other possibilities that could explain why lengthy treatments of antibiotics are required in most chronically ill patients to achieve significant mycoplasma suppression that would allow patient recovery [300, 307, 415] .

A major clinical problem seen during mycoplasma infections is caused by inflammation. This can be especially problematic in pathogenic mycoplasmal infections, and it is most troublesome when multiple infections are involved [416] . The most obvious example of this is that inflammatory cytokines are often produced and released into the circulation during pathogenic mycoplasmal infections [316, 320, 322] . Importantly, the blood levels of inflammatory cytokines have been correlated to patient morbidity [289] . In patients with severe mycoplasma infections inflammation can be serious, and anti-inflammatory treatments are often necessary [415] . In children who have severe M. pneumoniae infections corticosteroid treatment was associated with clinical and radiographic improvements. Such anti-inflammatory therapy was considered important in reducing patient signs and symptoms [417] . In mycoplasma cases with severe inflammation patients have J o u r n a l P r e -p r o o f Journal Pre-proof been treated with steroids or other immunosuppressive drugs with or without intravenous administration of immunoglobulins [418] .

Various natural supplements have been used to reduce inflammation during mycoplasma infections. Some natural cytokine inhibitors to reduce inflammation, such as alpha-lipoic acid (ALA), have been added as dietary supplements. ALA has also been shown to be a good inhibitor of inflammatory cytokines in rheumatoid arthritis patients [419] . Other herbs and vegetables, such as curcumin, broccoli seed extracts, cordyceps, Chinese skullcap, Isatis and Houttuynia extracts, have also been used to specifically reduce inflammation during mycoplasma infections (review [300] ). In addition to ALA, other supplements, such as L-carnitine, ALA, CoQ10, and other components, especially membrane glycerophospholipids [420] , have been used to support mitochondrial function [421] .

After antibiotic therapies for mycoplasma infections are discontinued, patients often require additional anti-microbial treatments to prevent relapse [300] . Thus, some herbal supplements have been added to treatment strategies during and after antibiotics have been stopped. Most of these herbs and natural remedies have not been tested in controlled clinical trials with mycoplasmainfected patients, but there is some indication that they can be useful (reviewed in [300] ).

Human beings are exposed to infectious diseases from microorganisms adapted to the evolution of mankind and some other unexpected ones appearing as emergent or reemergent diseases. These latter microorganisms affect public health and produce unexpected outbreaks. We have considered here some examples of microorganisms that are mostly intracellular pathogens, such as viruses and mycoplasma. As they invade host cells intracellularly, they are more difficult to treat, diagnose and prevent, and they can easily spread among the population causing outbreaks of the diseases they promote with significant morbidity and sometimes, mortality and sequelae in J o u r n a l P r e -p r o o f Journal Pre-proof human populations. We have briefly reviewed the current knowledge of the main biological, pathogenic, diagnostic, treatment, and prevention issues regarding SARS-CoV-2, Zika virus and mycoplasmas, as this special issue deals, in particular, with such pathogens.

Great effort has been made bymany disciplines trying to understand why these pathogens promote various diseases and how we can stop these threats. The new techniques in biology that have matured during the last few years has allowed great advances in the topics covered in this review and will continue to evolve to include a more comprehensive data at the molecular and pathophysiological level of the diseases they promote worldwide. Understanding these will require not only new techniques, but a molecular explanation of the basis of these diseases as well as coordination to increase the accessibility of these advances to avoid the spread of emergent diseases.

The continuity of the human species requires knowing how these before-mentioned pathogens 

The authors confirm that there is no conflict of interest.

Gonzalo Ferreira thanks the support from CSIC - Table 1 . Reported observations and recommendations of SARS-CoV-2 infections in offspring, placenta, and mother.

Before delivery -rare or no vertical transmission (ACE2 receptors and TMPRS22 expressed) [191] .

-increase in fetal death [223] -rare [218] -Symptomatic cases of infection (higher risk of severe disease with the presence of comorbidities) [228] -Pre-eclampsia like complications [216] After delivery Neonates -usually not infected [212] -if infected with symptoms (translate to NICU) [214] -if present (villitis and malperfusion) [221] Recommended actions -Vaccination (any stage during pregnancy) [229] -Breastfeeding (it can transfer antibodies) [232] J o u r n a l P r e -p r o o f Table 2 . Reported observations and recommendations in ZIKA Virus infections in offspring, placenta, and mother.

Before delivery -vertical transmission (CZS with microcephaly, because of positive viral neurotropism) [272] , and multisystemic symptoms that might not configure a CZS [271] .

-increase in intrauterine growth restriction, hepatitis < anemia [271] -villous immaturity -macrophages hyperplasia [284] -Symptomatic cases of infection (treatment like the rest of the adult population, though intensive studies should be performed in the offspring due to the likely vertical transmission) [270] .

-Diagnostic tests (RT-PCR, seroconversion, others) [267, 268] .

Neonates infection -maculopapular rash, conjunctivitis, joint pain, fever [279, 280] -placentomegaly [271] Recommended actions -Prevention (avoid mosquito bites, sexual intercourse in ZIKV infected adults, 2 months for females and up to 6 months for men) [292] -Breastfeeding (though ZIKV is found in milk breastfeeding should not stop) [ 

Emerging and reemerging infectious diseases

The challenge of emerging and re-emerging infectious diseases

Emerging infectious diseases and outbreaks: Implications for outbreak-A n update on the status

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Structural basis of receptor recognition by SARS-CoV-2

Virological assessment of hospitalized patients with COVID-2019

COVID-19: consider cytokine storm syndromes and immunosuppression

Cytokine release syndrome in severe COVID-19

Origin and evolution of pathogenic coronaviruses

of Novel Coronavirus-Infected Pneumonia

SARS-CoV-2: characteristics and current advances in research

The coronavirus E protein: Assembly and beyond, Viruses

Structural model of the SARS coronavirus E channel in LMPG micelles

Expression of SARS-coronavirus envelope protein in Escherichia coli cells alters membrane permeability

Structure of a conserved golgi complex-targeting signal in coronavirus envelope proteins

Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3

Differential patterns of amantadine-resistance in influenza A (H3N2) and (H1N1) isolates in Toronto, Canada

Coronavirus envelope protein: Current knowledge

Sars

Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics?

Membrane binding proteins of coronaviruses

Sequence analysis of the bovine coronavirus nucleocapsid and matrix protein genes

The structure of the membrane protein of sars-cov-2 resembles the sugar transporter semisweet

A thermostable, closed SARS-CoV-2 spike protein trimer

Renin-angiotensin-aldosterone system and COVID-19 infection

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Cathepsin L Functionally Cleaves the Severe

Acute Respiratory Syndrome Coronavirus Class I Fusion Protein Upstream of Rather than Adjacent to the Fusion Peptide

Severe acute respiratory syndrome coronavirus spike protein counteracts BST2-mediated restriction of virus-like particle release

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Distinct conformational states of SARS-CoV-2 spike protein

Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2

Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains

The spike protein of SARS-CoV -A target for vaccine and therapeutic development

The intracellular sites of early replication and budding of SARS-coronavirus

The coronavirus nucleocapsid is a multifunctional protein

Biochemical characterization of SARS-CoV-2 nucleocapsid protein

Coronaviruses: An overview of their replication and pathogenesis

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response

Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-β signaling

RNA binding domain reveals potential unique drug targeting sites

The Molecular Biology of Coronaviruses

The Novel Human Coronaviruses NL63 and HKU1

Proteolytic processing of polyproteins 1a and 1ab between non-structural proteins 10 and 11/12 of Coronavirus infectious bronchitis virus is dispensable for viral replication in cultured cells

An efficient ribosomal frame-shifting signal in the polymerase-encoding region of the coronavirus IBV

Ultrastructure and Origin of Membrane Vesicles Associated with the Severe Acute Respiratory Syndrome Coronavirus Replication Complex

Coronaviruses post-SARS: Update on replication and pathogenesis

Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage

Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

Making Sense of Mutation: What D614G

Means for the COVID-19 Pandemic Remains Unclear

On the origin and continuing evolution of SARS-CoV-2

Variant analysis of SARS-cov-2 genomes

Emergence of genomic diversity and recurrent mutations in SARS-CoV-2

A genetic barcode of SARS-CoV-2 for monitoring global distribution of different clades during the COVID-19 pandemic

of the I.C. on T. of Viruses., The species Severe acute respiratory syndrome

Comprehensive annotations of the mutational spectra of SARS-CoV-2 spike protein: A fast and accurate pipeline

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Covid-19: What have we learnt about the new variant in the UK?

The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations -SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology -Virological

Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ∆H69/V70

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

The coronavirus is mutating-does it matter?

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

Escape from neutralizing antibodies 1 by SARS-CoV-2 spike protein variants

Geographic and Genomic Distribution of SARS-CoV-2

2) SARS-CoV-2 variant of concern following vaccination

First identification of SARS-CoV-2 Lambda (C.37) variant in Southern Brazil

Clinical features of patients infected with 2019 novel coronavirus in

Coronavirus (SARS-CoV-2) and Mortality Rate in India: The Winning Edge

Rate of intensive care unit admission and outcomes among patients with coronavirus: A systematic review and Meta-analysis

Blood type and outcomes in patients with COVID-19

Relationship between ABO blood group distribution and J o u r n a l P r e -p r o o f clinical characteristics in patients with COVID-19

Assessment of health information about COVID-19 prevention on the internet: Infodemiological study

Assessment of the SARS-CoV-2 basic reproduction number, R0, based on the early phase of COVID-19 outbreak in Italy

Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia

Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: An observational cohort study

Characteristic temporary loss of taste and olfactory senses in SARS-CoV-2-positive-individuals with mild symptoms

Modeling the Onset of Symptoms of COVID-19

Persistent symptoms in patients after acute COVID-19

Time is of the essence: Impact of delays on effectiveness of contact tracing for COVID-19, a modelling study

Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study

The Interpretation of SARS-CoV-2 Diagnostic Tests

Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China

Chinese Center for Disease Control and Prevention

Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis

Detection of COVID-19: A review of the current literature and future perspectives

Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis

The incidence of the novel coronavirus SARS-CoV-2 patients: A systematic review

Early Spread of SARS-Cov-2 in the Icelandic Population

Infections and Transmission in a Skilled Nursing Facility

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Viral load of SARS-CoV-2 in clinical samples

Negative nasopharyngeal and oropharyngeal swabs do not rule out COVID-19

False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence

Van den Bruel, Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Evaluation of a rapid diagnostic assay for detection of sars-cov-2 antigen in nasopharyngeal swabs

Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples

Van den Bruel, Antibody tests for identification of current and past infection with SARS-CoV-2

Diagnostic accuracy of serological tests for covid-19: Systematic review and meta-analysis

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing

COVID-19 Coronavirus: Is Infection along with <i>Mycoplasma</i> or Other Bacteria Linked to Progression to a Lethal Outcome?

Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?

Medical management of COVID-19: treatment options under consideration

Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Effects of chloroquine on viral infections: An old drug against today's diseases?

Use of chloroquine in viral diseases

Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells

COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

Lysosomes as dynamic regulators of cell and organismal homeostasis

Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-α, interleukin 6, and interferon-γ production by peripheral blood mononuclear cells

Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial

Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world

The role of hydroxychloroquine in the age of COVID-19: A periodic systematic review and meta-analysis

Colchicine for the Treatment of Myocardial Injury in Patients With Coronavirus Disease 2019 (COVID-19)-An Old Drug With New Life?

The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design

Colchicine may not be effective in COVID-19 infection; it may even be harmful?

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Convalescent plasma as a potential therapy for COVID-19

Ivermectin: an award-winning drug with expected antiviral activity against COVID-19

Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

REGN-COV2, a Neutralizing Antibody Cocktail

Updated approaches against SARS-CoV-2

Plea for multitargeted interventions for severe COVID-19

Targeting COVID-19 Inflammation and Oxidative Stress

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

The versatile heparin in COVID-19

The prophylaxis and treatment potential of supplements for COVID-19

Nutrition Therapy for Severe Viral Infections (COVID-19): Recommendations and Considerations for Integrative Medical Treatments

Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?

Ascorbic Acid in COVID-19

Role of vitamin D in preventing of COVID-19 infection, progression and severity

What can we learn from Israel's rapid roll out of COVID 19 vaccination?

Strategic planning for Covid-19

Epidemiology Based on Current Evidence

tropical medicine reports Bottazzi, The SARS-CoV-2 vaccine pipeline: an overview

Human Pre-Implantation Embryos Are Permissive To Sars-Cov-2 Entry

receptor ACE2 and the protease TMPRSS2 suggests susceptibility of the human embryo in the first trimester

The SARS-CoV-2 receptor ACE2 expression of maternalfetal interface and fetal organs by single cell transcriptome study

The effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal-fetal transmission: a systematic review and meta-analysis

Infections in pregnancy with Covid-19 and other respiratory RNA virus diseases are rarely, if ever, transmitted to the fetus: Experiences with coronaviruses, parainfluenza, metapneumovirus respiratory syncytial virus, and influenza

Transplacental transmission of SARS-CoV-2 infection

Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis

Lack of vertical transmission of severe acute respiratory syndrome Coronavirus 2, China, Emerg

Profile of a killer: the complex biology powering the coronavirus pandemic

A single mutation in the prM protein of Zika virus contributes to fetal microcephaly

Viral respiratory disease in pregnancy

Why are pregnant women susceptible to COVID-19? An immunological viewpoint

Binding of SARS-CoV-2 to Cell Receptors: A Tale of Molecular Evolution

The association between SARS-CoV-2 infection and preterm delivery: a prospective study with a multivariable analysis

The risk of COVID-19 for pregnant women: Evidences of molecular alterations associated with preeclampsia in SARS-CoV-2 infection

COVID-19 in an Intrauterine Growth Restriction (IUGR) Infant with Congenital Heart Disease: Case Report and Literature Review

Potential effects of SARS-CoV-2 infection during pregnancy on fetuses and newborns are worthy of attention

COVID-19 (SARS-CoV-2) Infection in Pregnancy: A Systematic Review

Covid-19 during pregnancy and adverse outcomes: Concerns and recommendations from the brazilian teratology information service

Definition and categorization of the timing of mother-tochild transmission of SARS-CoV-2, World Health Organization

Association of Maternal SARS-CoV-2 Infection in Pregnancy with Neonatal Outcomes

Neonatal SARS-CoV-2 Infection: Practical Tips

SARS-CoV-2 Infection and the Newborn

Clinical outcomes of maternal and neonate with COVID-19 infection -Multicenter study in Saudi Arabia

SARS-CoV-2 infection of the placenta

SARS-CoV-2 colonization of maternal and fetal cells of the human placenta promotes alteration of local reninangiotensin system

Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission

Does the human placenta express the canonical cell entry mediators for SARS-CoV-2?

Fetal and placental infection with SARS-CoV-2 in early pregnancy

Placental Pathology Findings during and after SARS-CoV-2 Infection: Features of Villitis and Malperfusion

Sars-cov-2 and placenta: New insights and perspectives

Diffuse trophoblast damage is the hallmark of SARS-CoV-2-associated fetal demise

SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers

Term Human Placental Trophoblasts Express SARS-CoV-2 Entry Factors ACE2, TMPRSS2, and Furin

Compromised SARS-CoV-2-specific placental antibody transfer

The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from

Risk factors for illness severity among pregnant women with confirmed SARS-CoV-2 infection -Surveillance for Emerging Threats to Mothers and Babies Network, 22 state, local, and territorial health departments

Pregnant people deserve the protection offered by

SARS-CoV-2 vaccines

SARS-CoV-2 Vaccination During Pregnancy: A Complex Decision

Efficient maternofetal transplacental transfer of anti-SARS-CoV-2 spike antibodies after antenatal SARS-CoV-2 BNT162b2 mRNA vaccination

SARS-CoV-2-Specific Antibodies in Breast Milk after COVID-19 Vaccination of Breastfeeding Women

Zika Virus

Available from

Zika virus: history, epidemiology, transmission, and clinical presentation

An updated review of Zika virus

Zika virus (II). Pathogenicity and physical properties

Zika virus: A report on three cases of human infection during an epidemic of jaundice in Nigeria

Zika virus in Brazil and worldwide: a narrative review

Zika Virus: a review of literature

Detection of zika virus in urine

Zika virus: From pathogenesis to disease control

Zika virus: A review of literature

Zika virus infection: global update on epidemiology and potentially associated clinical manifestations

Mechanisms of Zika Virus Infection and Neuropathogenesis

Structural biology of Zika virus and other flaviviruses

The 3.8A cryo-EM structure of Zika Virus

Zika virus -emergence, evolution, pathology, diagnosis, and control: current global scenario and future perspectives -a comprehensive review

Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade

West Nile virus infection and immunity

Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody

Biology of Zika Virus Infection in Human Skin Cells

infectious diseases Sardi, Zika virus outbreak, bahia, brazil

Current Zika virus epidemiology and recent epidemics

Zika Virus Infection -After the Pandemic

Zika Virus Outbreak on Yap Island, Federated States of Micronesia

Potential sexual transmission of zika virus

Guillain-Barré Syndrome Outbreak Associated With Zika Virus Infection in French Polynesia: A Case-Control Study

Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection

An update on Zika virus infection

Pathophysiology and Mechanisms of Zika Virus Infection in the Nervous System

Routes for Vertical Transmission

The IFITMs Inhibit Zika Virus Replication

A CRISPR screen defines a signal peptide processing pathway required by flaviviruses

Interim Guidelines for Pregnant Women During a Zika Virus Outbreak -United States

Interim Guidelines for the Evaluation and Testing of Infants with Possible Congenital Zika Virus Infection -United States

Diagnostic testing for Zika virus: A postoutbreak update

Times to key events in Zika virus infection and implications for blood donation: A systematic review

Guidance for U.S. Laboratories Testing for

Dengue and zika viruses: Epidemiological history, potential therapies, and promising vaccines

Zika virus during pregnancy: From maternal exposure to congenital Zika virus syndrome

Characterizing the pattern of anomalies in congenital zika syndrome for pediatric clinicians

Neurotropism and behavioral changes associated with Zika infection in the vector Aedes aegypti article

Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice

Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses

Zika virus genome biology and molecular pathogenesis

Zika Virus-Induced Microcephaly and Its Possible Molecular Mechanism

Zika virus and microcephaly: A review of the molecular interactions

Zika virus: A review of literature

Perinatal Case Fatality Rate Related to Congenital Zika Syndrome in Brazil: A Cross-Sectional Study

Infectious Zika viral particles in breastmilk

Evidence for Mother-to-Child Transmission of Zika Virus Through Breast Milk

Breast milk transmission of the context of Zika virus: A systematic review

Zika virus infection at different pregnancy stages: Anatomopathological findings, target cells and viral persistence in placental tissues

Prenatal and perinatal environmental influences on the human fetal and placental epigenome

IL-1β and TGF-β weaken the placental barrier through destruction of tight junctions: An in vivo and in vitro study

Type III Interferons Produced by Human Placental Trophoblasts Confer Protection against Zika Virus Infection

Zika virus infection of Hofbauer cells

Zika Virus Vaccine: Progress and Challenges

Update: Interim Guidance for Preconception Counseling and Prevention of Sexual Transmission of Zika Virus for Men with Possible Zika Virus Exposure -United States

Evolution of the innate and adaptive immune response in women with acute Zika virus infection

Zika virus increases risk of dengue disease

Zika virus associated with sensory polyneuropathy

Molecular biology and genetics of mycoplasmas (Mollicutes)

Mycoplasma genomics: Tailoring the genome for minimal life requirements through reductive evolution

Essential genes of a minimal bacterium

Ureaplasma carriage in pregnant women: The prevalence of transmission from mother to newborn

Chronic Illnesses: General Considerations in Selecting Conventional and Integrative Treatments

Mycoplasmas: Sophisticated, Reemerging, and Burdened by Their Notoriety

Molecular biology and pathogenicity of mycoplasmas

Mycoplasma genitalium: From chrysalis to multicolored butterfly

Role of mycoplasmal infections in fatigue illnesses: Chronic fatigue and fibromyalgia syndromes, gulf war illness and rheumatoid arthritis

Ureaplasma: Current perspectives

Diagnosis and Treatment of Chronic Mycoplasmal Infections in Fibromyalgia and Chronic Fatigue Syndromes: Relationship to Gulf War Illness, Inst

Diagnosis and Integrative Treatment of Intracellular Bacterial Infections in Chronic Fatigue and Fibromyalgia Syndromes, Gulf War Illness, Rheumatoid Arthritis and other Chronic Illnesses

Mycoplasma genitalium, an emerging sexually transmitted pathogen

Global research trends of World Health Organization's top eight emerging pathogens

Interaction of mycoplasmas with host cells

Molecular basis of size and antigenic variation of a Mycoplasma hominis adhesin encoded by divergent vaa genes

The Unique Microbiology and Molecular Pathogenesis of Mycoplasma genitalium

Mycoplasma genitalium P140 and P110 cytadhesins are reciprocally stabilized and required for cell adhesion and terminal-organelle development

Identification and characterization of immunogenic proteins of Mycoplasma genitalium

The Role of Lipoproteins in Mycoplasma-Mediated Immunomodulation

Cytokines as the good predictors of refractory Mycoplasma pneumoniae pneumonia in school-aged children

Mycoplasma fermentans-derived lipid inhibits class II major histocompatibility complex expression without mediation by interleukin-6, interleukin-10, tumor necrosis factor, transforming growth factor-β, type I interferon, prostaglandins or nitric oxide

Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration

In vitro influence of Mycoplasma penetrans on activation of peripheral T lymphocytes from healthy donors or human immunodeficiency virus-infected individuals

Induction of cytokines and chemokines in human monocytes by mycoplasma fermentans-derived lipoprotein MALP-2

Spiralin, a mycoplasmal membrane lipoprotein, induces T-cell-independent B-cell blastogenesis and secretion of proinflammatory cytokines

Insights into the pathogenesis of Mycoplasma pneumoniae (Review)

Role of Mycoplasma penetrans endonuclease P40 as a potential pathogenic determinant

Membrane-associated nuclease activities in mycoplasmas

Effects of Mycoplasma fermentans on the myelomonocytic lineage: Different molecular entities with cytokine-inducing and cytocidal potential

Apoptotic cell death of human T lymphoblastoid cells induced by arginine deiminase

Identification and purification of arginine deiminase that originated from Mycoplasma arginini

Comparison of PCR, culture & serological tests for the diagnosis of Mycoplasma pneumoniae in community-acquired lower respiratory tract infections in children

Pathogenesis of Mycoplasma pneumoniae: An update

Subversion of the immune response by human pathogenic mycoplasmas

Structure of CARDS toxin, a unique ADPribosylating and vacuolating cytotoxin from Mycoplasma pneumoniae

Mycoplasma pneumoniae CARDS toxin induces pulmonary eosinophilic and lymphocytic inflammation

A Potentially Severe Infection

Mycoplasmas: Brain invaders?

Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis

Chronic bacterial and viral infections in neurodegenerative and neurobehavioral diseases

Multiple co-infections (Mycoplasma, Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: Association with signs and symptoms

Mycoplasma pneumoniae from the respiratory tract and beyond

Diagnosis and treatment of mycoplasmal infections in J

Persian Gulf War illness-cfids patients

Some Considerations when Undergoing Treatment for Chronic Illnesses and Autoimmune Diseases Antibiotic and Nutraceutical Therapy for Chronic Infections Found in Most Chronic Illnesses

Inactivated Mycoplasma Pneumoniae Vaccine: Evaluation in Volunteers

Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications

Cell mediated immune response following Mycoplasma pneumoniae infection in man. I. Lymphocyte stimulation

A compendium for Mycoplasma pneumoniae

Isolation of Mycoplasma hominis and Ureaplasma urealyticum from amniotic fluid at 16-20 weeks of gestation: potential effect on outcome of pregnancy

Ureaplasma urealyticum intrauterine infection: Role in prematurity and disease in newborns

Ureaplasma urealyticum and Premature Birth

Ureaplasma and BPD

Different degrees of maternal Ureaplasma colonization and its correlation with bronchopulmonary dysplasia in <32 weeks' preterm infants

Role of Ureaplasma Respiratory Tract Colonization in Bronchopulmonary Dysplasia Pathogenesis: Current Concepts and Update

Coexistence of Ureaplasma and chorioamnionitis is associated with prolonged mechanical ventilation

Lung pathology in premature infants with Ureaplasma urealyticum infection

Ureaplasma Infection and Neonatal Lung Disease

Systemic Neonatal Infection Due to Ureaplasma urealyticum

Neonatal CNS infection and inflammation caused by Ureaplasma species: Rare or relevant?

Amnionitis with Ureaplasma urealyticum or other microbes leads to increased morbidity and prolonged hospitalization in very low birth weight infants

Ureaplasma-associated prenatal, perinatal, and neonatal morbidities

Comparison of two identification and susceptibility test kits for Ureaplasma spp and Mycoplasma hominis in amniotic fluid of patients at high risk for intraamniotic infection

Association between genital mycoplasmas, acute chorioamnionitis and fetal pneumonia in spontaneous abortions

Ureaplasma urealyticum, Mycoplasma hominis and adverse pregnancy outcomes

Positive culture rate and antimicrobial susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum

The Alabama Preterm Birth Study: Umbilical cord blood Ureaplasma urealyticum and Mycoplasma hominis cultures in very preterm newborn infants

Ureaplasma urealyticum and Mycoplasma hominis presence in umbilical cord is associated with pathogenesis of funisitis

Neonatal mycoplasma and ureaplasma infections

Genital tract infection and associated factors affect the reproductive outcome in fertile females and females undergoing in vitro fertilization

Mycoplasma genitalium-an up-date

Intra-amniotic infection with ureaplasma parvum causes preterm birth and neonatal mortality that are prevented by treatment with clarithromycin

Placental Infection with Ureaplasma species is Associated with Histologic Chorioamnionitis and Adverse Outcomes in Moderately Preterm and Late-Preterm Infants

Placental features of chorioamnionitis colonized with ureaplasma species in preterm delivery

Clinical significance of intra-amniotic inflammation in patients with preterm premature rupture of membranes

Mycoplasmas and ureaplasmas as neonatal pathogens

Intraamniotic infection in low-birth-weight infants

The role of the multiple banded antigen of Ureaplasma parvum in intraamniotic infection: major virulence factor or decoy?

Ureaplasma species multiple banded antigen (MBA) variation is associated with the severity of inflammation In vivo and In vitro in human placentae

Differential recognition of the multiple banded antigen isoforms across Ureaplasma parvum and Ureaplasma urealyticum species by monoclonal antibodies

Common sulfoglycolipid receptor for mycoplasmas involved in animal and human infertility

Intracellular fate of Ureaplasma parvum entrapped by host cellular autophagy

Funisitis and chorionic vasculitis: The histological counterpart of the fetal inflammatory response syndrome

The fetal inflammatory response syndrome

Cerebral palsy and fetal inflammatory response syndrome: A review

A systemic fetal inflammatory response and the development of bronchopulmonary dysplasia

Chorioamnionitis increases neonatal morbidity in pregnancies complicated by preterm premature rupture of membranes

Clair, A prospective, controlled study of maternal and perinatal outcome after intra-amniotic infection at term

The effect of chorioamnionitis on perinatal outcome in preterm gestation

journal of obstetrics Duff, gynecology, Progress in pathogenesis and management of clinical intraamniotic infection

Chorioamnionitis and intraamniotic infection

Diagnosis and management of clinical chorioamnionitis

Epidural analgesia and intrapartum fever: Placental findings

Pathophysiology, diagnosis, and management of intraamniotic infection

Term maternal and neonatal complications of acute chorioamnionitis

Antibiotics for preterm rupture of membranes

Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes: A randomized controlled trial

Use of prophylactic antibiotics in labor and delivery

Antibiotic therapy for chorioamnionitis to reduce the global burden of associated disease

The relationship between intrapartum maternal fever and neonatal acidosis as risk factors for neonatal encephalopathy

Planned early birth versus expectant management (waiting) for prelabour rupture of membranes at term (37 weeks or more), Cochrane Database Syst

Treatment of mycoplasma pneumonia: A systematic review

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities

Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae

Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum

Comparative susceptibilities of various AIDS-associated and human urogenital tract mycoplasmas and strains of Mycoplasma pneumoniae to 10 classes of antimicrobial agent in vitro

Tetracyclineresistant Mycoplasma hominis strains contain streptococcal tetM sequences

Dissemination of the tetM tetracycline resistance determinant to Ureaplasma urealyticum

Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis

Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics

Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae

No visible dental staining in children treated with doxycycline for suspected rocky mountain spotted fever

Clinical and laboratory profiles of refractory Mycoplasma pneumoniae pneumonia in children

New Horizons in Mycoplasma genitalium Treatment

The Jarisch-Herxheimer reaction after antibiotic treatment of spirochetal infections: A review of recent cases and our understanding of pathogenesis

Precision medicine: Retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/ post-treatment Lyme disease syndrome: Part 1

Persister cells, dormancy and infectious disease

Precision Medicine: The Role of the MSIDS Model in

Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome and Other Chronic Illness: Part 2

Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children

Pathogenesis and treatment of neurologic diseases associated with mycoplasma pneumoniae infection

Effects of Alpha-Lipoic Acid Supplementation on

Inflammatory Biomarkers and Matrix Metalloproteinase-3 in Rheumatoid Arthritis Patients

Membrane Lipid Replacement for chronic illnesses, aging and cancer using oral glycerolphospholipid formulations with fructooligosaccharides to restore phospholipid function in cellular membranes, organelles, cells and tissues

Mitochondrial dysfunction and chronic disease: Treatment with membrane lipid replacement and other natural supplements

A new coronavirus associated with human respiratory disease in China

Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome